Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Trial details
- Registry ID
- NCT06207370
- Drugs studied
- Tafenoquine
TrialRedline tracks 4 clinical trials sponsored by 60 Degrees Pharmaceuticals LLC: 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for BabesiosisNCT06207370 | Tafenoquine | Recruiting | 2027-03-01Estimated |
| B-FREE Chronic Babesiosis StudyNCT06656351 | Tafenoquine 100mg | Recruiting | 2027-02Estimated |
| Tafenoquine in Patients With Mild to Moderate COVID-19NCT04533347 | Tafenoquine Oral Tablet | Completed | 2022-06-30Actual |
| Long-Term Safety Study of TafenoquineNCT03320174 | Tafenoquine | Completed | 2021-07-13Actual |
Names as written in the registry records.